Scarica l'app Stockscreener
0.7154
1.65%
0.0116
Dopo l'orario di chiusura:
.68
-0.0354
-4.95%
Precedente Chiudi:
$0.7038
Aprire:
$0.71
Volume 24 ore:
108.61K
Relative Volume:
0.05
Capitalizzazione di mercato:
$8.19M
Reddito:
$285.80K
Utile/perdita netta:
$-12.60M
Rapporto P/E:
-0.3624
EPS:
-1.9743
Flusso di cassa netto:
$-13.44M
1 W Prestazione:
+2.20%
1M Prestazione:
-19.17%
6M Prestazione:
-51.66%
1 anno Prestazione:
-61.74%
Intervallo 1D:
$0.6655
$0.73
Intervallo di 1 settimana:
$0.60
$0.8056
Portata 52W:
$0.548
$2.11
Aprea Therapeutics Inc Stock (APRE) Company Profile
Nome
Aprea Therapeutics Inc
Settore
Industria
Telefono
215-948-4119
Indirizzo
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.7154 | 8.19M | 285.80K | -12.60M | -13.44M | -1.9743 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-06-22 | Iniziato | H.C. Wainwright | Neutral |
| 2020-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2019-10-28 | Iniziato | JP Morgan | Neutral |
| 2019-10-28 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
APRE PE Ratio & Valuation, Is APRE Overvalued - Intellectia AI
APRE SEC FilingsAprea Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Soleus entities and Guy Levy report 1.27M shares in Aprea (NASDAQ: APRE) - Stock Titan
Aprea Therapeutics (APRE) CFO buys pre-funded and common warrants - Stock Titan
Aprea Therapeutics (APRE) director buys pre-funded and common stock warrants - Stock Titan
Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement - bitget.com
Aprea Therapeutics Raises $30M to Advance Oncology Pipeline - TipRanks
Weekly Earnings: Is Aprea Therapeutics Inc stock a buy or sell2026 Big Picture & Fast Gain Stock Tips - baoquankhu1.vn
Aprea Therapeutics closes $30 million private placement - Investing.com
Aprea Therapeutics closes $30 million private placement By Investing.com - Investing.com India
Aprea closes oversubscribed $30M private placement to fund APR-1051 clinical expansion - TradingView
Aprea Therapeutics (NASDAQ: APRE) closes $30M oversubscribed funding - Stock Titan
Cancer drug developer Aprea raises $30M to expand APR-1051 study - Stock Titan
Aug Fed Impact: How does Aprea Therapeutics Inc perform in inflationary periods2026 Volume Leaders & AI Optimized Trade Strategies - baoquankhu1.vn
Aprea Therapeutics (NASDAQ:APRE) Given Outperform Rating at Wedbush - Defense World
Aprea reports 2025 results, early data for APR-1051 trial - MSN
Aprea Therapeutics Announces $30 Million Private Placement - The Globe and Mail
APRE: Wedbush Reiterates 'Outperform' Rating with $7 Target | AP - GuruFocus
Aprea reports confirmed tumor response in WEE1 inhibitor trial - Investing.com
Aprea Therapeutics raises $30 million in private placement By Investing.com - Investing.com Australia
Aprea reports confirmed tumor response in WEE1 inhibitor trial By Investing.com - Investing.com Australia
Aprea Therapeutics (NASDAQ:APRE) versus Ocugen (NASDAQ:OCGN) Head-To-Head Comparison - Defense World
Aprea’s $30 million funding may lead to significant dilution with the 2028 deadline approaching - bitget.com
Aprea Therapeutics, Inc. announced that it has received $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc - MarketScreener
Aprea Therapeutics (Nasdaq: APRE) secures $30M and reports WEE1 trial response - Stock Titan
Aprea Therapeutics, Inc. announced that it expects to receive $30.0204 million in funding from Soleus Capital LLC, Vestal Point Capital, LP, Squadron Capital Management Llc and other investors - marketscreener.com
Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial - bitget.com
Aprea Reports Confirmed Partial Response In APR-1051 Trial And Announced $30M Private Placement - RTTNews
Aprea Therapeutics raises $30 million in private placement - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Cancer drug developer raises $30M to fund lead trial into 2028 - Stock Titan
After a 50% drop, an endometrial tumor shrank again on APR-1051 - Stock Titan
EPS Watch: How cyclical is Aprea Therapeutics Incs revenue streamQuarterly Trade Report & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Risk Hedge: How cyclical is Aprea Therapeutics Incs revenue stream - baoquankhu1.vn
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update - Defense World
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen - MSN
Aprea to present at Oppenheimer Healthcare Conference - MSN
Price Action: Is Aprea Therapeutics Inc affected by consumer sentimentMarket Movers & Daily Chart Pattern Signals - baoquankhu1.vn
Market Review: Is Aprea Therapeutics Inc a potential multi baggerRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Aprea Reports 2025 Results, Early Data for APR-1051 Trial - MyChesCo
Aprea Therapeutics advanced cancer trial shows promising results, stock soars - MSN
[EFFECT] Aprea Therapeutics, Inc. SEC Filing - Stock Titan
Aprea Therapeutics (APRE) registers 12.58M shares from Jan 2026 private placement - Stock Titan
Wedbush Keeps Their Buy Rating on Aprea Therapeutics (APRE) - The Globe and Mail
Aprea Therapeutics Inc Azioni (APRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):